Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 September 2025 | Story Anthony Mthembu | Photo Lunga Luthuli
Martin Nyaka
Martin Nyaka, Second Deputy Secretary General of the South African Union of Students (SAUS).

Martin Nyaka, Secretary General of the 2024-2025 Institutional Student Representative Council (ISRC) and Policy and Transformation Officer (CSRC) on the Bloemfontein Campus of the University of the Free State (UFS), has been elected as Second Deputy Secretary General (DSG) of the South African Union of Students (SAUS)

Nyaka was elected during the first leg of the SAUS conference, held in Gqeberha from 10-13 July 2025. His election is historic, as this is the first time the union has appointed a second DSG. In his new role, he joins the National Executive Council (NEC) alongside the SAUS President, Deputy President, Secretary General, Treasurer-General, and the First DSG.  

“It is a great honour for me to have represented the University of the Free State at this important platform, and I remain deeply grateful for the support and assistance I received from the institution throughout this journey,” said Nyaka. He will serve in this role until the next election in 2028. 

 

Anticipated impact

Nyaka explained that his decision to stand for election was influenced by challenges he and his SRC colleagues encountered when addressing certain student-related issues. He noted that some concerns, such as those linked with the National Student Financial Aid Scheme (NSFAS), can only be resolved at a national level. 

“This position places us in a better position to assist students and to ensure that our students are funded,” he said.  

In addition to his role as Second DSG, Nyaka also chairs the SAUS Monitoring and Evaluation portfolio, which oversees several sub-committees within the organisation.  

 

Lessons from leadership 

As his SRC term draws to a close, Nyaka reflected on the lessons he will carry into this new role. 

“Previously, as student leaders our mindset was very radical, and if ever things would not go our way, we would take to the streets,” he explained. “However, over this last term, the SRC resolved matters and reached agreements with management without protest. An important lesson I take with me is that radicalism is not always the answer. In an organisation like SAUS, we need to sit down and have discussions with stakeholders when there is a deadlock.”

Nyaka emphasised that what excites him most about the opportunity is the chance to work alongside student-leaders from across the country who are equally committed to making a meaningful impact.  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept